All In Biotech

Free tool

FAERS Monitor: Letybo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761225 or its brand name (Letybo, Letibotulinumtoxina-Wlbg). Reports on generic versions are filed under their own applications.

Reports

293

Serious

30

10% of reports

Hospitalization

20

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • therapy non-responder143
  • drug effect less than expected81
  • botulism15
  • drug ineffective15
  • headache11
  • off label use10
  • product quality issue10
  • dysphagia9
  • dyspnoea8
  • injection site pain8
  • chest discomfort7
  • eyelid ptosis6
  • muscular weakness6
  • patient dissatisfaction with treatment6
  • product temperature excursion issue6

Reports by year received

View as table
YearReports
20246
2025138
2026149

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,866 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
botulismSignal151325.8806.018,218
drug effect less than expectedSignal81394.5327.631,255
therapy non-responderSignal143229.1203.732,216
patient dissatisfaction with treatmentSignal6224.2101.41,116
product temperature excursion issueSignal683.938.0412
eyelid ptosisSignal642.419.2203
dysphagiaSignal96.83.639
product quality issueSignal105.32.931
chest discomfortSignal74.92.418
muscular weaknessSignal63.81.710
injection site pain81.90.92
headache111.30.70
dyspnoea81.00.50
off label use100.80.40
drug ineffective150.80.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.